On July 29, INSILICO fell 5.31% in regular trading, trading at 40.58 HKD/share, with turnover of HKD 183 million. The decline extends a multi-day selloff, following a 5.07% drop on July 28.

On the news front, the company announced that its AI-driven pan-TEAD inhibitor ISM6331 has been granted Fast Track Designation by the U.S. FDA for treating unresectable malignant pleural mesothelioma in adult patients who have progressed after prior anti-PD-1 antibody therapy and platinum-based chemotherapy. ISM6331 previously received FDA Orphan Drug Designation in 2024 and completed first patient dosing in a global Phase I trial in January 2025. Additionally, the Phase I clinical data for ISM6331 has been accepted for oral presentation at ESMO 2026 in October.

Despite these positive developments, the stock has continued to decline from its July 27 intraday high of 49.50 HKD. Within the Life Sciences Tools and Services sector, WUXI BIO rose 1.14%, WUXI APPTEC rose 0.13%, while XTALPI fell 4.21%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)